Gideon Hirschfield

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5619400/publications.pdf

Version: 2024-02-01

299 papers	30,117 citations	9234 74 h-index	5364 164 g-index
331 all docs	331 docs citations	331 times ranked	28857 citing authors

#	Article	IF	Citations
1	C-reactive protein: a critical update. Journal of Clinical Investigation, 2003, 111, 1805-1812.	3.9	2,941
2	C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. New England Journal of Medicine, 2004, 350, 1387-1397.	13.9	2,608
3	The gut microbiota and host health: a new clinical frontier. Gut, 2016, 65, 330-339.	6.1	1,719
4	C-reactive protein: a critical update. Journal of Clinical Investigation, 2003, 111, 1805-1812.	3.9	1,673
5	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology, 2017, 67, 145-172.	1.8	889
6	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	13.9	817
7	Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006, 440, 1217-1221.	13.7	621
8	Primary Biliary Cirrhosis Associated withHLA, IL12A,andIL12RB2Variants. New England Journal of Medicine, 2009, 360, 2544-2555.	13.9	569
9	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011, 43, 1131-1138.	9.4	501
10	Primary sclerosing cholangitis. Lancet, The, 2013, 382, 1587-1599.	6.3	484
11	Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. Journal of Hepatology, 2011, 54, 374-385.	1.8	470
12	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	0.6	470
13	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
14	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
15	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
16	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	9.4	339
17	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	0.6	330
18	Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2010, 105, 2186-2194.	0.2	291

#	Article	IF	Citations
19	The UKâ€PBC risk scores: Derivation and validation of a scoring system for longâ€term prediction of endâ€stage liver disease in primary biliary cholangitis. Hepatology, 2016, 63, 930-950.	3.6	269
20	The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 303-330.	9.6	264
21	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nature Communications, 2015, 6, 8019.	5.8	245
22	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
23	Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches. Gastroenterology, 2010, 139, 1481-1496.	0.6	222
24	Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. Gastroenterology, 2014, 146, 430-441.e6.	0.6	217
25	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut, 2018, 67, 1568-1594.	6.1	217
26	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 655-657.	9.4	205
27	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	3.6	204
28	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558.	1.8	202
29	C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 793-807.	0.2	199
30	NOTCH2mutations in Alagille syndrome. Journal of Medical Genetics, 2012, 49, 138-144.	1.5	197
31	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	6.1	195
32	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8309-8314.	3.3	194
33	IgG4-related Sclerosing Disease: Autoimmune Pancreatitis and Extrapancreatic Manifestations. Radiographics, 2011, 31, 1379-1402.	1.4	192
34	The evolution of cellular deficiency in GATA2 mutation. Blood, 2014, 123, 863-874.	0.6	189
35	OX40, OX40L and Autoimmunity: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2016, 50, 312-332.	2.9	187
36	Inflammation and Endothelial Function. Circulation, 2005, 111, 1530-1536.	1.6	175

#	Article	IF	Citations
37	British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut, 2019, 68, 1356-1378.	6.1	168
38	Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 93-110.	8.2	161
39	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet, The, 2017, 389, 1114-1123.	6.3	157
40	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy, 2017, 49, 588-608.	1.0	154
41	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	1.8	148
42	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human Molecular Genetics, 2012, 21, 5209-5221.	1.4	139
43	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	6.1	139
44	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology, 2016, 63, 1357-1367.	3.6	133
45	The gut-adherent microbiota of PSCâ€“IBD is distinct to that of IBD. Gut, 2017, 66, 386.1-388.	6.1	132
46	Characterization of animal models for primary sclerosing cholangitis (PSC). Journal of Hepatology, 2014, 60, 1290-1303.	1.8	129
47	The Genetics of Complex Cholestatic Disorders. Gastroenterology, 2013, 144, 1357-1374.	0.6	126
48	Seladelpar (MBX-8025), a selective PPAR-Î´ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. The Lancet Gastroenterology and Hepatology, 2017, 2, 716-726.	3.7	126
49	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. Journal of Hepatology, 2018, 68, 92-99.	1.8	126
50	Primary biliary cholangitis. Lancet, The, 2020, 396, 1915-1926.	6.3	126
51	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. Journal of Hepatology, 2019, 70, 483-493.	1.8	124
52	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 436-442.	3.0	123
53	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The Lancet Gastroenterology and Hepatology, 2019, 4, 445-453.	3.7	116
54	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	2.9	114

#	Article	IF	Citations
55	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of Hepatology, 2014, 60, 1249-1258.	1.8	113
56	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	1.8	111
57	Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 147-158.	8.2	110
58	Review article: overlap syndromes and autoimmune liver disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 517-533.	1.9	109
59	The immunogenetics of primary biliary cirrhosis: A comprehensive review. Journal of Autoimmunity, 2015, 64, 42-52.	3.0	109
60	Combined ursodeoxycholic acid (<scp>UDCA</scp>) and fenofibrate in primary biliary cholangitis patients with incomplete <scp>UDCA</scp> response may improve outcomes. Alimentary Pharmacology and Therapeutics, 2016, 43, 283-293.	1.9	109
61	Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 247-292.	9.6	107
62	Highâ€throughput Tâ€cell receptor sequencing across chronic liver diseases reveals distinct diseaseâ€associated repertoires. Hepatology, 2016, 63, 1608-1619.	3.6	104
63	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	3.7	103
64	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut, 2015, 64, 948-956.	6.1	101
65	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proofâ€ofâ€concept study. Hepatology, 2016, 64, 189-199.	3.6	101
66	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology, 2014, 60, 931-940.	3.6	99
67	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoEâ^'/â^' mice. Atherosclerosis, 2008, 196, 248-255.	0.4	96
68	Using GWAS to identify genetic predisposition in hepatic autoimmunity. Journal of Autoimmunity, 2016, 66, 25-39.	3.0	94
69	Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology, 2020, 159, 915-928.	0.6	94
70	Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut, 2021, 70, 1989-2003.	6.1	91
71	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Journal of Hepatology, 2017, 66, 1265-1281.	1.8	87
72	The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal of Autoimmunity, 2019, 105, 102328.	3.0	86

#	Article	IF	Citations
73	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	0.6	82
74	Loss of CD28 Expression by Liver-Infiltrating T Cells Contributes to Pathogenesis of Primary Sclerosing Cholangitis. Gastroenterology, 2014, 147, 221-232.e7.	0.6	81
75	A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. Journal of Crohn's and Colitis, 2020, 14, 935-947.	0.6	81
76	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. Hepatology, 2017, 65, 907-919.	3.6	79
77	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes and Immunity, 2012, 13, 328-335.	2.2	78
78	The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation. PLoS Biology, 2018, 16, e2005046.	2.6	78
79	Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 631-644.	1.9	77
80	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	1.8	77
81	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. Seminars in Liver Disease, 2020, 40, 034-048.	1.8	76
82	The IRF5â€“TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	1.4	74
83	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.2	74
84	Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. Journal of Autoimmunity, 2016, 68, 98-104.	3.0	70
85	Klinefelter's syndrome (47,XXY) is in excess among men with SjÃ¶gren's syndrome. Clinical Immunology, 2016, 168, 25-29.	1.4	68
86	Mesenchymal stromal cells and liver fibrosis: a complicated relationship. FASEB Journal, 2016, 30, 3905-3928.	0.2	67
87	Progress in the Genetics of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2011, 31, 147-156.	1.8	66
88	Antiâ€kelchâ€like 12 and antiâ€hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver International, 2015, 35, 642-651.	1.9	66
89	Expert clinical management of autoimmune hepatitis in the real world. Alimentary Pharmacology and Therapeutics, 2017, 45, 723-732.	1.9	66
90	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary Pharmacology and Therapeutics, 2019, 50, 1127-1136.	1.9	66

#	Article	IF	Citations
91	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.2	64
92	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. Journal of Hepatology, 2022, 76, 841-849.	1.8	64
93	CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. Arthritis and Rheumatism, 2009, 60, 931-937.	6.7	63
94	Comparative MRI Analysis of Morphologic Patterns of Bile Duct Disease in IgG4-Related Systemic Disease Versus Primary Sclerosing Cholangitis. American Journal of Roentgenology, 2014, 202, 536-543.	1.0	63
95	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
96	The Phenotypic Expression of Inflammatory Bowel Disease in Patients with Primary Sclerosing Cholangitis Differs in the Distribution of Colitis. Digestive Diseases and Sciences, 2013, 58, 2608-2614.	1.1	60
97	Mechanisms of tissue injury in autoimmune liver diseases. Seminars in Immunopathology, 2014, 36, 553-568.	2.8	60
98	Autoantibodies and Liver Disease: Uses and Abuses. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 225-231.	1.8	59
99	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatology Communications, 2019, 3, 365-381.	2.0	58
100	Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology, 2019, 69, 2120-2135.	3.6	58
101	PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC). PLoS ONE, 2014, 9, e112877.	1.1	57
102	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology, 2016, 63, 644-659.	3.6	57
103	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	2.4	57
104	Good Maternal and Fetal Outcomes for Pregnant Women WithÂPrimary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1179-1185.e1.	2.4	56
105	Unmet clinical need in autoimmune liver diseases. Journal of Hepatology, 2015, 62, 208-218.	1.8	56
106	Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Scientific Reports, 2018, 8, 9189.	1.6	56
107	The Spectrum of Sclerosing Cholangitis and the Relevance of IgG4 Elevations in Routine Practice. American Journal of Gastroenterology, 2012, 107, 56-63.	0.2	55
108	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	3.6	55

#	Article	IF	Citations
109	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. Journal of Hepatology, 2021, 74, 321-329.	1.8	55
110	The interâ€rrelationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 1039-1050.	1.9	54
111	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
112	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scandinavian Journal of Gastroenterology, 2016, 51, 329-336.	0.6	53
113	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes and Immunity, 2013, 14, 179-186.	2.2	52
114	Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut, 2018, 67, 1135-1145.	6.1	52
115	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Review of Clinical Pharmacology, 2016, 9, 13-26.	1.3	51
116	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. Journal of Hepatology, 2021, 75, 634-646.	1.8	51
117	A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 980-990.	1.9	50
118	Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clinical and Experimental Immunology, 2017, 188, 394-411.	1.1	50
119	Amyloidosis: new strategies for treatment. International Journal of Biochemistry and Cell Biology, 2003, 35, 1608-1613.	1.2	49
120	Gilbert's syndrome: an overview for clinical biochemists. Annals of Clinical Biochemistry, 2006, 43, 340-343.	0.8	49
121	Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2016, 61, 1692-1699.	1.1	49
122	Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. Journal of Hepatology, 2017, 66, 116-122.	1.8	49
123	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. JHEP Reports, 2019, 1, 437-445.	2.6	48
124	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	1.8	47
125	The specificity of fatigue in primary biliary cirrhosis: Evaluation of a large clinic practice. Hepatology, 2010, 52, 562-570.	3.6	46
126	Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. Liver International, 2012, 32, 510-518.	1.9	45

#	Article	IF	Citations
127	Identifying opportunities to improve management of autoimmune hepatitis: Evaluation of drug adherence and psychosocial factors. Journal of Hepatology, 2012, 57, 1299-1304.	1.8	45
128	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2785-2792.e3.	2.4	43
129	Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. Clinical Gastroenterology and Hepatology, 2019, 17, 1379-1387.e3.	2.4	43
130	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. Frontiers in Endocrinology, 2020, 11, 575843.	1.5	43
131	Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. Journal of Autoimmunity, 2017, 77, 45-54.	3.0	42
132	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
133	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	3.6	42
134	Treatment of autoimmune liver disease: current and future therapeutic options. Therapeutic Advances in Chronic Disease, 2013, 4, 119-141.	1.1	40
135	Autoimmune hepatitis: an approach to disease understanding and management. British Medical Bulletin, 2015, 114, 181-191.	2.7	40
136	Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clinical Gastroenterology and Hepatology, 2018, 16, 278-287.e7.	2.4	40
137	Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. American Heart Journal, 2004, 147, 1071-1077.	1.2	39
138	Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis. JHEP Reports, 2019, 1, 286-296.	2.6	39
139	Insights into the management of Wilsonâ€™s disease. Therapeutic Advances in Gastroenterology, 2017, 10, 889-905.	1.4	39
140	Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-Î³ secreting cells. Journal of Autoimmunity, 2018, 94, 143-155.	3.0	38
141	Amyloidosis: a clinico-pathophysiological synopsis. Seminars in Cell and Developmental Biology, 2004, 15, 39-44.	2.3	37
142	Proximity to transplant center and outcome among liver transplant patients. American Journal of Transplantation, 2019, 19, 208-220.	2.6	37
143	Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 2451-2461.e3.	2.4	37
144	Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: Evidence for a gene-gene interaction. Hepatology, 2010, 52, 223-229.	3.6	36

#	Article	IF	Citations
145	Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Reports, 2021, 3, 100255.	2.6	36
146	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. Journal of Hepatology, 2022, 77, 353-364.	1.8	36
147	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology, 2012, 55, 1495-1506.	3.6	35
148	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2017, 69, 2187-2192.	2.9	35
149	Prevalence and Risk Factors for Liver Biochemical Abnormalities in Canadian Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 254-261.	1.0	34
150	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2018, 48, 951-960.	1.9	34
151	Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Reports, 2021, 3, 100217.	2.6	34
152	Human C-Reactive Protein Does Not Protect against Acute Lipopolysaccharide Challenge in Mice. Journal of Immunology, 2003, 171, 6046-6051.	0.4	33
153	Grand round: Autoimmune hepatitis. Journal of Hepatology, 2019, 70, 773-784.	1.8	33
154	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	1.8	33
155	Patients With Autoimmune Hepatitis Who Have Antimitochondrial Antibodies Need Long-term Follow-up to Detect Late Development of Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2012, 10, 682-684.	2.4	31
156	Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab. Journal of Hepatology, 2013, 59, 186-189.	1.8	31
157	A validated clinical tool for the prediction of varices in PBC: The Newcastle Varices in PBC Score. Journal of Hepatology, 2013, 59, 327-335.	1.8	31
158	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterology, 2016, 16, 71.	0.8	31
159	High-definition PBC: biology, models and therapeutic advances. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 76-78.	8.2	31
160	Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 957-965.	1.8	31
161	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. Hepatology Communications, 2018, 2, 421-436.	2.0	31
162	A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Scientific Reports, 2020, 10, 15308.	1.6	31

#	Article	IF	Citations
163	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. Liver International, 2022, 42, 112-123.	1.9	31
164	Recipient HLA-DR3, tumour necrosis factor-Î± promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are inter-related risk factors for chronic rejection of liver grafts. Journal of Hepatology, 2001, 34, 711-715.	1.8	30
165	Antimitochondrial Antibody-Negative Primary Biliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 323-331.	1.0	30
166	The Pathogenesis of Autoimmune Liver Disease. Digestive Diseases, 2016, 34, 327-333.	0.8	30
167	The impact of ileal pouchâ€anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2018, 48, 322-332.	1.9	30
168	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	2.4	30
169	Diagnosis of primary biliary cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 701-712.	1.0	29
170	Preventative hepatology: minimising symptoms and optimising care. Liver International, 2008, 28, 922-934.	1.9	28
171	Realâ€World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. Hepatology Communications, 2020, 4, 1332-1345.	2.0	28
172	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	6.1	28
173	Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis. JHEP Reports, 2019, 1, 369-376.	2.6	27
174	The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude. Clinical Gastroenterology and Hepatology, 2021, 19, 2587-2596.	2.4	27
175	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	0.6	27
176	Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. International Journal of Experimental Pathology, 2014, 95, 209-215.	0.6	26
177	A liver mass post-Fontan operation. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 571-572.	0.2	25
178	The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. Clinical Liver Disease, 2020, 15, 110-114.	1.0	25
179	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1248-1257.	2.4	25
180	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 1878-1885.	0.2	24

#	Article	IF	Citations
181	Review article: pathophysiology and management of primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1150-1164.	1.9	24
182	Primary biliary cirrhosis: one disease with many faces. Israel Medical Association Journal, 2011, 13, 55-9.	0.1	24
183	Cholestasis and cholestatic syndromes. Current Opinion in Gastroenterology, 2009, 25, 175-179.	1.0	23
184	Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease. Journal of Hepatology, 2016, 64, 1190-1193.	1.8	23
185	Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Digestive Diseases, 2017, 35, 267-274.	0.8	23
186	Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. BMJ Open, 2017, 7, e015081.	0.8	23
187	Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a crossâ€disease cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1213-1219.	1.9	23
188	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. Liver International, 2021, 41, 535-544.	1.9	23
189	IgG4 Related disease â€“ a retrospective descriptive study highlighting Canadian experiences in diagnosis and management. BMC Gastroenterology, 2013, 13, 168.	0.8	22
190	Genetics in PBC: What Do the â€œRisk Genesâ€•Teach Us?. Clinical Reviews in Allergy and Immunology, 2015, 48, 176-181.	2.9	22
191	The Immunogenetics of Autoimmune Cholestasis. Clinics in Liver Disease, 2016, 20, 15-31.	1.0	22
192	Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver International, 2019, 39, 967-975.	1.9	22
193	Hepatocellular carcinoma for the non-specialist. BMJ: British Medical Journal, 2009, 339, b5039-b5039.	2.4	21
194	Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity. EBioMedicine, 2019, 50, 3-4.	2.7	21
195	The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. Hepatology, 2021, 74, 3269-3283.	3.6	21
196	Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ: British Medical Journal, 2008, 337, a423-a423.	2.4	21
197	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
198	Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. Hepatology Communications, 2021, 5, 1009-1020.	2.0	20

#	Article	IF	Citations
199	Wilson Disease: Canadian Perspectives on Presentation And Outcomes from an Adult Ambulatory Setting. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 333-339.	1.8	19
200	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. Liver International, 2020, 40, 382-392.	1.9	19
201	CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. Frontiers in Immunology, 2020, 11, 577655.	2.2	19
202	Genetic Determinants of Cholestasis. Clinics in Liver Disease, 2013, 17, 147-159.	1.0	18
203	New Approaches to Investigate Drug-Induced Hypersensitivity. Chemical Research in Toxicology, 2017, 30, 239-259.	1.7	18
204	Adult liver transplantation: what non-specialists need to know. BMJ: British Medical Journal, 2009, 338, b1670-b1670.	2.4	17
205	Immunogenetics in primary sclerosing cholangitis. Current Opinion in Gastroenterology, 2017, 33, 93-98.	1.0	17
206	Pathophysiology of primary biliary cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 17-25.	1.0	17
207	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	2.4	17
208	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. European Radiology, 2020, 30, 3735-3747.	2.3	17
209	A Comparison of Depression Screening Instruments in Hepatitis C and the Impact of Depression on Somatic Symptoms. Psychosomatics, 2011, 52, 433-440.	2.5	16
210	New insights into autoimmune liver diseases. Hepatology Research, 2008, 38, 745-761.	1.8	15
211	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver International, 2020, 40, 1121-1129.	1.9	15
212	Transient development of anti-mitochondrial antibodies accompanies autoimmune hepatitis-sclerosing cholangitis overlap. Gut, 2009, 58, 152-153.	6.1	14
213	Management of Primary Sclerosing Cholangitis: Conventions and Controversies. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 261-268.	1.8	14
214	An overview of the diagnosis and management of immunoglobulin G4â€“related disease. Cmaj, 2016, 188, 953-961.	0.9	14
215	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 1514-1522.	0.2	14
216	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. European Radiology, 2022, 32, 67-77.	2.3	14

#	Article	IF	Citations
217	Autoimmune liver disease for the non-specialist. BMJ: British Medical Journal, 2009, 339, b3305-b3305.	2.4	13
218	Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitisâ€“Inflammatory Bowel Disease. Hepatology Communications, 2018, 2, 960-971.	2.0	13
219	Reply to: â€œAST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosisâ€. Journal of Hepatology, 2014, 61, 1445-1446.	1.8	12
220	Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis. Hepatology, 2015, 61, 424-427.	3.6	12
221	Deciphering the biology of IgG4-related disease: specific antigens and disease?. Gut, 2018, 67, gutjnl-2017-314861.	6.1	12
222	Sex Disparity in Liver Transplant and Access to Living Donation. JAMA Surgery, 2021, 156, 1010.	2.2	12
223	Renaming primary biliary cirrhosisâ€”clarity or confusion?. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 678-679.	8.2	11
224	A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert Review of Gastroenterology and Hepatology, 2021, 15, 929-939.	1.4	11
225	Managing hepatitis C virus infection. BMJ: British Medical Journal, 2009, 338, b2366-b2366.	2.4	10
226	Toward the molecular dissection of primary biliary cirrhosis. Hepatology, 2009, 50, 1347-1350.	3.6	10
227	Aspects of the Pathophysiology of Primary Biliary Cirrhosis. Digestive Diseases, 2015, 33, 102-108.	0.8	10
228	Primary sclerosing cholangitis and the management of uncertainty and complexity. Frontline Gastroenterology, 2017, 8, 260-266.	0.9	10
229	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100191.	2.6	10
230	<scp>HLA</scp> haplotypes in primary sclerosing cholangitis patients of admixed and nonâ€European ancestry. Hla, 2017, 90, 228-233.	0.4	9
231	Quality of life and primary sclerosing cholangitis: The business of defining what counts. Hepatology, 2018, 68, 16-18.	3.6	9
232	Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. Clinical Gastroenterology and Hepatology, 2021, 19, 768-776.e10.	2.4	9
233	The Role of Attachment Style and Depression in Patients with Hepatitis C. Journal of Clinical Psychology in Medical Settings, 2013, 20, 227-233.	0.8	8
234	Overlap syndrome: A real syndrome?. Clinical Liver Disease, 2014, 3, 43-47.	1.0	8

#	Article	IF	Citations
235	Postâ€prophylaxis Toxoplasma chorioretinitis following donorâ€“recipient mismatched liver transplantation. Transplant Infectious Disease, 2016, 18, 805-808.	0.7	8
236	Should we screen for cirrhosis?. BMJ: British Medical Journal, 2017, 358, j3233.	2.4	8
237	Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines. Frontline Gastroenterology, 2019, 10, 316-319.	0.9	8
238	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. Alimentary Pharmacology and Therapeutics, 2021, 54, 689-698.	1.9	8
239	A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist. Gastroenterology and Hepatology, 2019, 15, 145-154.	0.2	8
240	Review: Current status of therapy in autoimmune liver disease. Therapeutic Advances in Gastroenterology, 2009, 2, 11-28.	1.4	7
241	Genetic Risks Link Autoimmune Hepatitis to Other Autoimmune Liver Disease. Gastroenterology, 2014, 147, 270-273.	0.6	7
242	Editorial : The Etiology of Intrahepatic Cholestasis of Pregnancy: Towards Solving a Monkey Puzzle. American Journal of Gastroenterology, 2014, 109, 85-88.	0.2	7
243	Making the most of new genetic risk factorsÂâ€“Âgenetic and epigenetic fine mapping of causal autoimmune disease variants. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 408-411.	0.7	7
244	Letter: histology is relevant for risk stratification in primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 192-193.	1.9	7
245	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Singleâ€Center Analysis. Liver Transplantation, 2021, 27, 1733-1746.	1.3	7
246	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver International, 2022, 42, 615-627.	1.9	7
247	Genetics of Autoimmune Liver Disease: A Brief Summary for Clinicians. Digestive Diseases, 2014, 32, e1-e6.	0.8	6
248	FRI-062-Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patientsâ€™ perspective. Journal of Hepatology, 2019, 70, e412-e413.	1.8	6
249	Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. Hepatology Communications, 2020, 4, 399-408.	2.0	6
250	Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. Hepatology, 2022, 76, 303-316.	3.6	6
251	Liver disease in the UK. Lancet, The, 2015, 385, 503.	6.3	5
252	Genetic Distinctions in Patients With Primary Sclerosing Cholangitis: Immunoglobulin G4 Elevations and HLA Risk. Gastroenterology, 2015, 148, 886-889.	0.6	5

#	Article	IF	Citations
253	Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. Frontline Gastroenterology, 2016, 7, 271-274.	0.9	5
254	Genetic association studies and the risk factors for developing the â€œImmunoâ€bileâ€logicâ€•disease primary biliary cholangitis. Hepatology, 2018, 67, 1620-1622.	3.6	5
255	Autoimmune hepatitis and complexities in management. Frontline Gastroenterology, 2019, 10, 77-87.	0.9	5
256	Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes. World Journal of Gastroenterology, 2016, 22, 9966.	1.4	5
257	Editorial: autoimmune hepatitis â€“ identifying options for treatment. Alimentary Pharmacology and Therapeutics, 2016, 43, 1236-1237.	1.9	4
258	Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Scientific Reports, 2017, 7, 7652.	1.6	4
259	The 6 C's of primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 1255-1256.	1.8	4
260	Liver disease in the young adult: the challenges and rewards. The Lancet Gastroenterology and Hepatology, 2019, 4, 248-254.	3.7	3
261	Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise. BMJ Open Gastroenterology, 2019, 6, e000226.	1.1	3
262	The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. EBioMedicine, 2022, 80, 104068.	2.7	3
263	T regulatory cells and autoimmune liver disease. Liver International, 2008, 28, 155-157.	1.9	2
264	Serum alkaline phosphatase in multidrug resistance 2 (Mdr2â€“/â€“) knockout mice is strain specific. Hepatology, 2016, 63, 346-346.	3.6	2
265	Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding. Hepatology, 2021, 73, 1618-1620.	3.6	2
266	The evolving potential of precision medicine in the management of autoimmune liver disease. , 2021, , 135-167.		2
267	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	2
268	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. Efficacy and Mechanism Evaluation, 2022, 9, 1-54.	0.9	2
269	Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms. Clinical Science, 2003, 104, 65P-66P.	0.0	1
270	Primary Biliary Cirrhosis: The Future. Clinics in Liver Disease, 2008, 12, 473-479.	1.0	1

#	Article	IF	Citations
271	Navigating the road to personalized medicine: Can we believe?. Cmaj, 2010, 182, 651-652.	0.9	1
272	Autoimmune hepatitis â€“ learning about your patients from their autoantibody profiles. Liver International, 2012, 32, 5-7.	1.9	1
273	Autoimmune liver disease: evaluating overlapping and cross-over presentationsâ€”a case-based discussion: TableÂ1. Frontline Gastroenterology, 2016, 7, 240-245.	0.9	1
274	Work in Progress. Clinics in Liver Disease, 2018, 22, 501-515.	1.0	1
275	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liverâ€Related Mortality Is Higher in Males?. Hepatology, 2021, 74, 2307-2307.	3.6	1
276	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. Canadian Liver Journal, 2021, 4, 401-425.	0.3	1
277	Primary Biliary Cholangitis: Clinical Insights Into Diagnosis and Staging. Gastroenterology and Hepatology, 2021, 17, 2-5.	0.2	1
278	P066 Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis. Journal of Crohn's and Colitis, 2022, 16, i173-i174.	0.6	1
279	Elevated Serum Aminotransferases. JAMA - Journal of the American Medical Association, 2022, 327, 580.	3.8	1
280	Evaluation of Bacterial Dna Probe Analysis in Valvular Heart Disease. Clinical Science, 2003, 104, 4P-4P.	0.0	0
281	The genetic study of primary biliary cirrhosis: Great hope, some caution. Current Gastroenterology Reports, 2008, 10, 187-189.	1.1	0
282	Book Review Liver Immunology: Principles and Practice Edited by M. Eric Gershwin, John M. Vierling, and Michael P. Manns. 486 pp., illustrated. Totowa, NJ, Humana Press, 2007. $169. 978-1-58829-818-8. New England Journal of Medicine, 2008, 358, 1874-1875.	13.9	0
283	Metagenomics and autoimmune liver disease: searching for the unknown. Liver International, 2009, 29, 319-320.	1.9	0
284	Overlap Syndromes. , 2012, , 782-789.		0
285	Secondary Sclerosing Cholangitis. , 2013, , 123-133.		0
286	Reply. Gastroenterology, 2015, 148, 860-861.	0.6	0
287	Reply. Gastroenterology, 2015, 149, 508-509.	0.6	0
288	Reply. Gastroenterology, 2016, 150, 1689-1690.	0.6	0

#	Article	IF	Citations
289	In Vitro and Ex Vivo Models to Study T Cell Migration Through the Human Liver Parenchyma. Methods in Molecular Biology, 2017, 1591, 195-214.	0.4	0
290	Preface. Digestive Diseases, 2017, 35, 303-303.	0.8	0
291	PWE-046â€...TH17 cells dominate the colonic mucosal immune response in primary sclerosing cholangitis associated colitis. , 2018, , .		0
292	Primary Biliary Cholangitis. , 2018, , 217-232.		0
293	Response to â€œIs the hubâ€andâ€spoke model of care delivery a possible answer to geographical variation in liver transplant outcomes?â€. American Journal of Transplantation, 2019, 19, 1248-1249.	2.6	0
294	Editorial: liver disease in secondary careâ€”â€˜money or your lifeâ€™. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 856-857.	1.9	0
295	A massive haematemesis. BMJ: British Medical Journal, 2010, 340, b5534-b5534.	2.4	0
296	The Diagnosis and Classification of Immune-Mediated Biliary Diseases. , 2014, , 111-122.		0
297	Genetics of Primary Sclerosing Cholangitis. , 2017, , 99-110.		0
298	Autoimmune Hepatitis and Crossover Syndromes. In Clinical Practice, 2017, , 203-226.	0.1	0
299	The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: Discussion. Gastroenterology and Hepatology, 2021, 17, 14-17.	0.2	0